Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 3Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Sarcoma, Myeloid 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 3Injections 2Idarubicin 2Gemtuzumab 2Filgrastim 2Decitabine 2veliparib 1fludarabine phosphate 1aldesleukin 1Whole-Body Irradiation 1Temozolomide 1Peripheral Blood Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Daunorubicin 1CPX-351 1Busulfan 1Bone Marrow Transplantation 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Gemtuzumab × 1 year × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡